Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Neuropharmacology. 2013 Feb 13;70:236–246. doi: 10.1016/j.neuropharm.2013.01.020

Figure 4. PPARγ mediates the inhibitory actions of pioglitazone on neuropathic pain.

Figure 4

The PPARγ antagonist GW9662 or its vehicle was administered 15 min prior to pioglitazone (10 mg/kg/d) or its vehicle. GW9662 reduced the anti-allodynic effects of pioglitazone on vF thresholds (A,D), cold allodynia (B,E), and pin prick hyperalgesia (C,F), but had no effect on its own (n = 4–12 per group). Values represent mean ± SEM. (A–C) Statistical significance (p<0.05 by Bonferroni post-tests after repeated measures 2-way ANOVA) between pioglitazone + vehicle and high (★), high + medium (†), or high + medium + low (‡) doses of GW9662 + pioglitazone denoted by symbols in parentheses. (D–F) Statistical significance (p<0.05 by Dunnett multiple comparison test after 1-way ANOVA) versus pioglitazone + vehicle group denoted by (★).

HHS Vulnerability Disclosure